The evidence points toward an overall protective effect in adult cohorts and no increase in completed suicide in younger populations.
Commentary|Slideshows|March 10, 2025
February's Special Report: Child and Adolescent Psychiatry
Discover key insights from February’s Special Report on child and adolescent psychiatry, exploring overlooked diagnoses, new research, and the complex impact of social media on youth mental health.
Advertisement
Advertisement
Related to this article
Review finds ADHD drugs may ease perimenopause brain fog and improve daily focus, but objective cognition gains remain unclear; larger safety and efficacy studies needed.
This study compared the efficacy and tolerability of the 5 second-generation antipsychotics that are currently FDA approved as adjunctive treatments for adults with MDD.
Real-world data show TRD costs spike during resistant episodes; Compass’ psilocybin COMP360 delivers durable symptom relief through 26 weeks, potentially easing resource strain.
Learn how clinicians tailor antidepressants by diagnosis, symptoms, adverse effects, and next-step strategies for treatment-resistant depression.
Explore major depression subtypes—from melancholic to inflammatory—and how they shape symptoms, biology, and treatment choices for better outcomes.
TRD often mislabels depression; learn why MDD heterogeneity demands tailored treatments and when “difficult-to-treat” fits better.
First US TRD Awareness Day spotlights treatment-resistant depression, urging earlier recognition, stigma-breaking support, and renewed hope for patients and caregivers.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Comparison of Atypical Antipsychotics as Adjunctive Treatments for Major Depressive Disorder
2
Improving but Not Feeling It: Anticipatory Anhedonia and Cognition
3
ADHD Medications for Managing Menopausal Brain Fog: Improvements in Subjective Executive Function
4
New Phase 2 Data on Bezisterim for the Treatment of Long COVID
5